DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants

Information source: University of Nebraska
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Renal Insufficiency

Intervention: Zoledronic Acid (Drug); calcium and Vitamin D (Drug); Alendronate (Drug)

Phase: N/A

Status: Active, not recruiting

Sponsored by: University of Nebraska

Official(s) and/or principal investigator(s):
Lynn Mack-Shipman, MD, Principal Investigator, Affiliation: University of Nebraska


The study is designed to look at the effect of different bone treatment plans on bone loss after kidney or kidney/pancreas transplant.

Clinical Details

Official title: Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplant

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percent change in Posterior Anterior (PA) spine bone density from baseline to 24 months post transplant

Secondary outcome:

Percent change in PA spine bone density from baseline to 12 months and percent change in total hip bone density from baseline to 24 months

Patient compliance will be quantified in the alendronate and placebo groups as the percentage of pills distributed that were taken. The occurence of side effects will be summarized using descriptive statistics and compared among the treatment groups.

Detailed description: The aims are to determine baseline bone mineral density (BMD) in kidney and kidney/pancreas transplant patients who will be randomized to weekly alendronate, annual zoledronic acid infusions or placebo (calcium with Vitamin D). These patients will be followed for two years with annual bone density testing as well as biochemical markers. A secondary aim is to evaluate compliance and tolerability of taking annual intravenous zoledronic acid versus weekly alendronate in the transplant recipient.


Minimum age: 19 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Transplant patients who have had a kidney or kidney/pancreas transplant in the last

150 days with adequate kidney function as defined by a calculated creatine clearance of 35ml/min or more and serum creatinine less than 3. 0 Exclusion Criteria:

- Dual X-ray Absorptiometry (DXA) T-score at the spine or hip of -3 or lower

- History of more than one vertebral or non-vertebral fracture in the past two years

- Abnormalities of the esophagus which delay esophageal emptying

- Inability to stay upright for 30 minutes

- Pregnant, nursing women or women not using an effective form of birth control

- Hypocalcemia

- Hypercalcemia

- Calculated creatinine clearance of <35 ml/min or serum creatinine > 3. 0

- Patients already treated with bisphosphonates within the past one year

- Patients unable to undergo DXA

- Patients with cancer

Locations and Contacts

University of Nebraska Medical Center, Omaha, Nebraska 68198, United States
Additional Information

Starting date: December 2003
Last updated: January 2, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017